Back to top
more

CVRx (CVRX)

(Real Time Quote from BATS)

$15.39 USD

15.39
1,027,523

+1.99 (14.85%)

Updated Nov 4, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Masimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

by Zacks Equity Research

CVRx announces the publication of positive study data for its Barostim therapy.

CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 16.34% and 2.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in CVRx (CVRX): Can Its 19.0% Jump Turn into More Strength?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Silk Road Medical (SILK): Can Its 24.0% Jump Turn into More Strength?

by Zacks Equity Research

Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CVRx (CVRX) Stock Jumps 33.9%: Will It Continue to Soar?

by Zacks Equity Research

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits

by Zacks Equity Research

CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.

New Strong Buy Stocks for January 30th

by Zacks Equity Research

HCC, EGO, WRLD, PBPB and CVRX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024.

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of 20% and 3.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes CVRx (CVRX) a Good Fit for 'Trend Investing'

by Zacks Equity Research

CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Boeing, McDonald's, Monster Beverage in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 44.44% and 3.15%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why 'Trend' Investors Would Love Betting on CVRx (CVRX)

by Zacks Equity Research

CVRx (CVRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know

by Zacks Equity Research

Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?

by Zacks Equity Research

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.

Recent Price Trend in CVRx (CVRX) is Your Friend, Here's Why

by Zacks Equity Research

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes CVRx (CVRX) a New Strong Buy Stock

by Zacks Equity Research

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.